New combo shows promise against Tough-to-Treat lymphoma

NCT ID NCT04569032

Completed Disease control Sponsor: Seagen, a wholly owned subsidiary of Pfizer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 35 times

Summary

This study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Results showed that many patients responded to the treatment, but side effects were common. This early-phase trial suggests the combo may be an option for this hard-to-treat cancer, but more research is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Azienda Ospedaliera Universitaria Integrata Verona Policlinico G.B. Rossi

Verona, 37134, Italy
Azienda Ospedaliero Universitaria di Bologna - IRCCS

Bologna, Emilia-Romagna, 40138, Italy
CHU Grenoble Alpes

Tranche, Auvergne-Rhône-Alpes, 38700, France
Cetir Centre Medic

Barcelona, 08029, Spain
Cleveland Clinic taussig Cancer Center Investigational Pharmacy

Cleveland, Ohio, 44106, United States
Cleveland Clinic, The

Cleveland, Ohio, 44195, United States
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Lombardy, 20122, Italy
Fondazione Irccs San Matteo

Pavia, Lombardy, 27100, Italy
Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS Candiolo - Oncologia Medica

Candiolo, Turin, 10060, Italy
Hammersmith Hospital

London, W12 0HS, United Kingdom
Hopital Emile Muller

Mulhouse, 68070, France
Hospital Clinico Universitario de Salamanca

Salamanca, 37007, Spain
Hospital Duran I Reynals - Institut Catala d'Oncologia

Barcelona, 08908, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario De La Paz

Madrid, Other, 28046, Spain
Höpital Haut Levéque - CHU Bordeaux Service d'hématologie clinique et thérapie cellulaire

Pessac, 33604, France
IEC Trials, Hospital La Milagrosa.

Madrid, Other, 28010, Spain
IRCCS Ospedale Policlinico San Martino

Genova, Other, 16132, Italy
MACMILLIAN Cancer Centre

London, WC1E 6AG, United Kingdom
Massey Cancer Center Clinical & Translational Research Lab

Richmond, Virginia, 23298, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center David H. Koch Center for Cancer Care

New York, New York, 10021, United States
Oxford University Hospitals

Headington, Oxford, OX3 7LE, United Kingdom
Rocky Mountain Cancer centers, LLP

Aurora, Colorado, 80012, United States
Rocky Mountain Cancer centers, LLP

Boulder, Colorado, 80303, United States
Rocky Mountain Cancer centers, LLP

Colorado Springs, Colorado, 80907, United States
Rocky Mountain Cancer centers, LLP

Denver, Colorado, 80218, United States
Rocky Mountain Cancer centers, LLP

Denver, Colorado, 80220, United States
Rocky Mountain Cancer centers, LLP

Lakewood, Colorado, 80228, United States
Rocky Mountain Cancer centers, LLP

Littleton, Colorado, 80120, United States
Rocky Mountain Cancer centers, LLP

Lone Tree, Colorado, 80124, United States
Rocky Mountain Cancer centers, LLP

Longmont, Colorado, 80504, United States
Rocky Mountain Cancer centers, LLP

Pueblo, Colorado, 81003, United States
Rocky Mountain Cancer centers, LLP

Thornton, Colorado, 80260, United States
Stanford Cancer Center

Stanford, California, 94305, United States
Stanford Hospital and Clinics, Investigational Drug Services

Stanford, California, 94305, United States
Texas Oncology - Central South (Balcones Dr)

Austin, Texas, 78731, United States
Texas Oncology - Central South (James Casey)

Austin, Texas, 78745, United States
Texas Oncology - Central/South Texas

Austin, Texas, 78705, United States
Texas Oncology-Northeast Texas

Longview, Texas, 75601, United States
Texas Oncology-Northeast Texas

Palestine, Texas, 75801, United States
Texas Oncology-Northeast Texas

Paris, Texas, 75460, United States
Texas Oncology-Northeast Texas

Tyler, Texas, 75702, United States
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Tulane Cancer Center

New Orleans, Louisiana, 70112, United States
Tulane Medical Center

New Orleans, Louisiana, 70112, United States
UCLH Hospitals

London, NWI 2BG, United Kingdom
US Oncology Investigational Products Center (IPC)

Irving, Texas, 75063, United States
US Oncology Investigational Products Center(IPC)

Irving, Texas, 75063, United States
US Oncology lnvestigational Products Center (IPC)

Irving, Texas, 75063, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35249, United States
VCU Massey Cancer Center-Radiation Oncology

Richmond, Virginia, 23219, United States
VCU Medical Center -InPatient

Richmond, Virginia, 23219, United States
VCU Medical Center Critical Care Hospital

Richmond, Virginia, 23219, United States
VCU at Stony Point

Richmond, Virginia, 23235, United States
Virginia Commonwealth University

Richmond, Virginia, 23219, United States
Virginia Oncology Associates

Chesapeake, Virginia, 23320, United States
Virginia Oncology Associates

Hampton, Virginia, 23666, United States
Virginia Oncology Associates

Newport News, Virginia, 23606, United States
Virginia Oncology Associates

Norfolk, Virginia, 23502, United States
Virginia Oncology Associates

Virginia Beach, Virginia, 23456, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

brentuximab vedotin (ADCETRIS) plus CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone)

What this could lead to

If successful, this combination could become a new frontline treatment option for certain types of PTCL that have low CD30 expression, potentially improving response rates.

What could go wrong

This is a small, early-phase (Phase 2) study with no control group, so results are preliminary. Side effects from chemotherapy and brentuximab vedotin can be serious, and long-term benefits are not yet proven.

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma angioimmunoblastic T-cell lymphoma enteropathy-associated T-cell lymphoma hepatosplenic T-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma monomorphic epitheliotropic intestinal T-cell lymphoma Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T CELL LYMPHOMA